Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 14INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Exanthema 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Doxycycline × Clear all
NCT01465802 2019-01-09

ARCHER 1042

Pfizer

Phase 2 Completed
236 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02239731 2018-02-27

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Vyne Therapeutics Inc.

Phase 2 Completed
24 enrolled

Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡